| | Aflatoonian et al. [15] 2008 | Sohrabvand et al. [16] 2009 | Abdelaal et al. [17] 2012 | Esinler et al. [14] 2013 | Bassiouny et al. [18] 2018 |
| Country | Iran | Iran | Egypt | Turkey | Egypt |
| Number of patients | 30 vs. 30 | 30 vs. 30 | 28 vs. 16 | 17 vs. 40 | 100 vs. 100 |
| Conflict of Interests | No stated | None declared | None declared | None declared | None declared |
| Signed informed consent | Yes | Yes | Yes | No stated | Yes |
| Period of enrollment | 7, 2006 and 7, 2007 | 4, 2006 to 3, 2007 | 3, 2010 and 8, 2011 | 2001-2011 | 10, 28, 2013, and 7, 31, 2015 |
| Study groups | 2 | 2 | 3 | 2 | 3 |
| Study design | Parallel design | Parallel design | Parallel design | Parallel design | Parallel design |
| Ethical Approval | Yes | Yes | Yes | Yes | Yes |
| Method of allocation | No stated | No stated | No stated | Through computerized IVF database system | sealed opaque envelopes |
| Proportion of IVF/ICSI | IVF or ICSI cycles | No stated | Only ICSI | Only IVF | IVF or ICSI cycles |
| Age(y) | 29.63±4.42 vs. 28.37±3.20 | 29.9 ± 3.6 vs. 29.2 ± 3.5 | 29.4 ± 3.7 vs. 27.4 ± 6.0 | 29.0 ± 5.1 vs. 30.2 ± 5.2 | 27.8 ± 3.7 vs. 27.7 ± 3.9 |
| Pituitary suppression | GnRH- agonist long protocol Buserelin | GnRH-agonist long protocol 0.5 mg/d Buserelin | GnRH-agonist long protocol 0.1 mg | leuprolide acetate | GnRH-agonist long protocol 0.1 mg of subcutaneous triptorelin |
| Follicle Stimulation | HMG | rFSH | HMG | rFSH | HMG |
| comparison | Cabergoline vs. Coasting | Cabergoline vs. Coasting | Cabergoline vs. Coasting vs. step-down | Cabergoline vs. Coasting | Cabergoline vs. Coasting vs. coastng with cabergoline |
| Triggering | HCG (10,000 IU) | HCG (10,000 IU) | HCG (10,000 IU) | HCG | HCG (10,000 IU) |
| intervention | 0.5 mg/d cabergoline for 8 days starting on day of hCG. | 0.5 mg/d cabergoline for 7 days starting on day of hCG. | 0.5 mg/d cabergoline for 8 days starting on day of hCG. | 0.5 mg/d cabergoline for 8 days starting on day of hCG. | 0.25 mg/d cabergoline for 8 days starting on day of hCG. |
| comparator | Coasting | Coasting | Coasting | Coasting | Coasting |
| RCT | Yes | Yes | Yes | Yes | Yes |
| Clinical pregnancy definition | The presence of gestational sac or cardiac activity 3 weeks after ET. | Sonographic detection of the gestational sac was confirmed. | A gestational sac or cardiac pulsation 3 weeks after ET. | Intrauterine gestational sac by transvaginal ultrasonography. | Visible intrauterine gestational sac on transvaginal ultrasonography. |
| Authors’ conclusions | Cabergoline was as effective as coasting in the prevention of early severe OHSS in high risk patients, but yielded more retrieved oocytes. | Cabergoline seems to be an effective, convenient, and safe drug for the prevention of OHSS. | Coasting may have a higher pregnancy rate and higher preventive method. | Cabergoline was effective to reduce moderate-severe OHSS without sacrificing pregnancy rates in patients at risk of developing OHSS | Combining coasting and cabergoline was associated with a lower OHSS rate compared with either therapy alone. |